Transparency Life Sciences (TLS), an all-digital clinical development services company, announced that the US Patent and Trademark Office issued a patent covering key aspects of the company’s “integrated approach combining data transparency, crowdsourced clinical protocol design and digital patient data collection.”
“This patent is considered especially significant given a high-profile 2014 Supreme Court ruling that set a high legal standard for software and business method intellectual property,” said TLS.
“The new TLS patent reinforces the distinctiveness of Transparency’s approach to clinical development that encompasses a broad class of therapeutic areas and clinical development stages.”
Marc Foster, COO of TLS, said: “This patent issuance for our core approach is the most recent sign that transparent, crowdsourced, digitally-executed clinical trials are gaining wide acceptance.
“TLS was the first to obtain FDA clearance for a crowdsourced, digitally-focused clinical trial.
“The FDA continues to demonstrate support for the innovative approaches we’ve pioneered by approving a digitally-executed, virtual trial for a new drug that leverages our proprietary technology.
“We have successfully implemented these approaches in central nervous system, autoimmune, cancer and other major therapeutic areas, and are now excited to make 21st Century clinical trials available to biopharma drug developers of all sizes.
“We expect that TLS’s expanding intellectual property estate, including this newly issued patent, will contribute to growing industry awareness and acceptance of novel clinical trial approaches and technologies.”